"The newest member of my biotech portfolio is CYTK, Cytokinetics. This is the latest new listing from Andrew Vaino at Roth Capital, Wall Street's best biotech analyst. CYTK develops small molecules to improve muscle function for the purpose of treating heart failure and Lou Gehrig's disease. Its clinical data looks promising, it has a good chance of achieving "orphan drug" status which helps with regulatory and clinical barriers, Amgen is subsidizing the development costs so it has a great partner, and the shares appear significantly undervalued. I'm loading up".
News 
Market Data 
Discover 
AI
